Free Trial
→ What Elon Musk's Cybercab Reveal Could Mean for Investors (From Brownstone Research) (Ad)tc pixel
OTCMKTS:VAXX

Vaxxinity Earnings Date & Estimates

Vaxxinity logo
$0.02 +0.01 (+14,900.00%)
As of 11/2/2026 10:26 AM Eastern

Vaxxinity is estimated to report earnings on Wednesday, November 11, 2026.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Vaxxinity

Vaxxinity is expected to post earnings of -$0.12 per share. Vaxxinity last reported on March 27, 2024, posting -$0.09 per share and beating the -$0.13 consensus estimate. Vaxxinity has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.12

Recent Track Record

Last Reported
Q4 2023
Last Quarter EPS
-$0.09 (Beat by +$0.04)
EPS Beat Rate
7 of last 8 quarters

Prepare for the Earnings Call

Vaxxinity Earnings FAQ

Vaxxinity (OTCMKTS:VAXX) is estimated to report earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Vaxxinity to post earnings of -$0.12 per share for the quarter.

Vaxxinity Earnings Headlines

Vaxxinity (OTCMKTS:VAXX) Shares Cross Above Two Hundred Day Moving Average - Here's What Happened
October 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31160852
Vaxxinity Inc.
May 25, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/vaxx/financials
80 Days Until the Pentagon Restricts Chinese Rare Earths
China controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports to the U.S. With a January 1, 2027 deadline approaching, the Pentagon selected four companies to build critical mineral processing facilities on U.S. military bases. Only one was chosen for heavy rare earths - a Nasdaq-listed firm with an Ohio metallurgy facility under Pentagon contracts and rights to 80% of output from a major Canadian processing plant.tc pixel
 |  The Tomorrow Investor (Ad)
Brain health
October 24, 2024  |  newsweek.comN
Treatment Trials in Alzheimer's Disease
September 30, 2024  |  msn.comhttps://www.msn.com/en-au/health/other/treatment-trials-in-alzheimer-s-disease/ar-BB1mwHGY
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
June 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/20/2901487/0/en/vaxxinity-ub-312-parkinson-s-trial-results-published-in-nature-medicine.html
See More Vaxxinity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxxinity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxxinity and other key companies, straight to your email.

About Vaxxinity

Vaxxinity (OTCMKTS:VAXX) Inc. is a biotechnology company focused on developing vaccines and immunotherapies for chronic diseases, including neurodegenerative conditions. The company’s approach is designed to stimulate the body’s immune system to target disease-related proteins or pathways, with the goal of addressing underlying disease biology rather than treating symptoms alone.

Vaxxinity’s research and development pipeline has included UB-311, an investigational vaccine targeting amyloid beta for Alzheimer’s disease, and UB-312, an investigational vaccine designed to target abnormal alpha-synuclein associated with Parkinson’s disease and other synucleinopathies. The company has also pursued programs in other chronic conditions, including migraine and metabolic or endocrine disorders. These products remain investigational and are subject to clinical testing and regulatory review.

The company was formerly known as United Neuroscience and adopted the Vaxxinity name as it broadened its focus on immune-based medicines. Vaxxinity is headquartered in the United States and has conducted development activities through international clinical and research collaborations. Mei Mei Hu, a co-founder of the company, has served as its chief executive officer.

View Vaxxinity Profile
Earnings Tools